Tolerance and safety of enalapril
|
|
- Loraine Gaines
- 6 years ago
- Views:
Transcription
1 Br. J. clin. Pharmac. (1984), 18, 249S-253S Tolerance and safety of enalapril W. McFATE SMITH, R. 0. DAVIES, M. A. GABRIEL, D. M. KRAMSCH, F. MONCLOA, JANET E. RUSH & J. F. WALKER Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486, USA 1 Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. 2 Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. 3 While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. 4 Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension. Keywords enalapril hypertension efficacy safety therapy Introduction Enalapril is the product of a targeted research programme to develop a non-sulphydryl containing angiotensin converting enzyme (ACE) inhibitor with a long duration of action and an improved safety profile for use in the management of hypertension and congestive heart failure. The objective of the clinical research programme for enalapril was to demonstrate efficacy in hypertension of all degrees of severity, alone and in conjunction with hydrochlorothiazide; effectiveness of a once-daily regimen; efficacy in congestive heart failure; short and long-term safety and acceptability, including the absence of specific adverse effects associated with the sulphydryl containing captopril. Studies on the efficacy of enalapril are presented elsewhere in this supplement. Safety and tolerability Approximately 3500 patients have been treated with enalapril to date. The exposure in controlled trials in normal volunteers and in patients with hypertension or congestive heart failure as filed for registration, includes 2249 subjects. Over 600 patients have been treated for more than 1 year and approximately 200 for over 2 years. In the controlled trials, investigators regularly monitored adverse experiences using nonleading questions. Additional emphasis was placed on those side-effects previously reported for captopril. The number of patients worldwide who received enalapril alone and those who received both enalapril and hydrochlorothiazide are shown in Table 1. These two groups are not mutually exclusive since some patients received enalapril alone initially, and subsequently received enalapril with hydrochlorothiazide. In the third group, mostly from clinical pharmacology studies, patients received enalapril with other antihypertensive agents other than hydrochlorothiazide. The placebo group includes patients with hypertension who received only placebo, and patients in congestive heart failure studies who received placebo plus diuretics and digitalis. Finally, a large number of patients received other antihypertensive drugs in comparative studies. 249S
2 250S Table 1 W. McFate Smith et al. Population observed for adverse experiences Enalapril alone 1855 Enalapril and hydrochlorothiazide 727 Enalapril and other antihypertensives 153 Placebo 317 Other antihypertensive agents 1628 Note: 2249 patients on enalapril. Skin rash Twenty-two patients on enalapril and eight further patients on enalapril with hydrochlorothiazide reported skin rash, but the drug was discontinued in only six patients (Table 2). This low incidence of skin rash is about twice that reported for patients receiving placebo, similar to that in patients receiving control drugs and considerably lower than captopril (see Table 7). Moreover, the complaint of skin rash was usually mild in the enalapril patients with only one severe skin rash being recorded. Taste disturbance Only one patient receiving enalapril alone reported transient taste loss (Table 3), and one further patient on the combination. Five patients reported taste loss in the group receiving control drugs, and all of these patients were receiving captopril. No patient had the drug discontinued because of taste loss in the enalapril group. A number of reports of altered taste were recorded probably because investigators were sensitive to the possibility of taste disturbances. These were not clinically important. White blood cell counts Neither neutropenia nor agranulocytosis was encountered using the Squibb/FDA definition of less than 300 neutrophils/mm3. As shown in Table 3 Incidence of taste disturbance Taste loss Taste alteration Enalapril alone 1* (0.1%) 8 (0.4%) Enalapril 1* (0.1%) 2 (0.3%) hydrochlorothiazide Placebo 0 0 Control drugs St (0.3%) 3 (0.2%) *Transient and disappeared on continued therapy. tall captopril. Table 4, an isolated value of 900 total white blood cells/mm3 was reported in one patient. All counts in the weeks before and after this observation were within normal limits; this one value was considered a probable laboratory error. In four patients, values between 1000 and 2500 cells/mm3 were reported. In a case report published by Studer & Vetter (1982), a count of 1700 mm3 total white cells following a single dose of 0.6 mg enalapril was noted. This patient also had fever and a transient skin rash. No similar occurrence has been reported in either patients or normal volunteers, and in this case the relationship to therapy may be questioned. A low white count was noted in one patient with systemic lupus erythematosis and scleroderma, who had been treated with captopril prior to receiving a week's therapy on enalapril. White counts were reduced by the disease itself and occurred during the captopril therapy prior to receiving enalapril. In subsequent months when the patient was off converting enzyme inhibitors, a similar haematological pattern recurred consistent with the possibility that the earlier low counts were manifestations of the disease rather than the treatment. Two additional isolated values were reported (Table 4) as the last value on therapy during a 4-week dose finding study. No follow-up data were available. Table 2 Incidence of skin rash (%) Treatment Number of cases Number discontinued Enalapril alone 22 (1.2%) 6 (0.3%) Severity (mild-moderate-severe) [12-8-1] [1-4-1] Enalapril/hydrochlorothiazide 8 (1.1%) 0 Placebo 2 (0.6%) 0 Control drugs 14 (0.9%) 4 (0.3%) Severity (mild-moderate-severe) [9-5-0] [2-24]
3 Tolerance and safety of enalapril Table 4 Number of cases of decreased total white blood cell counts (n = 1657) Per mm3 Values less than 1000/mm3 Isolated value in one case 900 Laboratory error Values between 1000 and 2500/mm3 Studer & Vetter case (1982) 1700 Single 0.6 mg dose Enalapril vs hydrochlorothiazide 2300 Last value on therapy Enalapril vs hydrochlorothiazide 2400 Last value on therapy SLE/scleroderma (CUP) 1900 Previous captopril CUP = compassionate use protocol; SLE = systemic lupus erythematosis. 251S Additionally, when mean white counts were analysed across the total groups, there was no trend suggesting a decrease in white blood cell count overall. Renal effects Uraemia Because of the importance of the renin-angiotensin system in renal function and especially the physiological contribution of angiotensin II, patients were carefully screened to select those patients with essential hypertension and normal renal function for controlled studies prior to initiating studies in patients with renal disease. Overall, renal function was well-maintained with only a small number of patients developing mild and reversible increases in serum creatinine (Table 5). Eleven cases (0.6%), eight of whom were receiving concomitant hydrochlorothiazide, were reported. In the control population, the incidence was 0.26%. One case from this group experienced a reversible increase in serum creatinine and glycosuria but no hyperglycaemia or aminoaciduria (Cressman et al., 1982). The increases were seen after hydrochlorothiazide was added to previous enalapril therapy but reversed when enalapril was discontinued and the thiazide maintained. There was no evidence of underlying renovascular hypertension in this patient. One additional patient in this group received concomitant lithium therapy and this may have been a factor in the uraemia. Elevated serum creatinines were also encountered in the congestive heart failure studies. Overall, the incidence was higher than in the hypertensive patients but was similar in the enalapril and placebo patients. Uraemia was encountered in some patients with bilateral renovascular hypertension. Eight cases in which increases in serum creatinine were seen and related to known or subsequently diagnosed bilateral renovascular hypertension are shown in Table 6. Six of the eight were also receiving diuretics. Uraemia reversed when enalapril or diuretic was discontinued. This phenomenon has been observed with both captopril and enalapril (Hricik et al., 1983) and is thought to be associated with angiotensin II dependency. A prospective study in patients with renovascular hypertension is continuing with careful monitoring of renal function and about a quarter of those with bilateral renal artery stenosis have developed uraemia. Proteinuria Routine collections of 12- or 24-h urinary protein were undertaken in Phase III studies. No case of nephrotic syndrome or membranous glomerulonephritis has been reported on enalapril. Only one patient had a major elevation (3-4 g/day) in urinary protein, this following transurethral resection in a patient with severe congestive heart failure. In hypertension studies, a few isolated, slightly abnormal values were reported in six patients in the enalapril group and in three patients on control therapy. In no case was there a pattern obviously related to therapy, and in most cases values returned to within the normal range during continued Table S Number (%) of patients developing elevated serum creatinine Hypertension Enalapril * (0.66%) Control (0.26%) Congestive heart failure Enalapril/diuretic (4.2%) Control 59 3 (5.1%) *Eight patients on concomitant thiazide. n
4 252S W. McFate Smith et al. Table 6 Uraemia in renal vascular hypertension Creatinine (mgldl) Bilateral Baseline Treatment Diuretic stenosis Comments No Yes Previous uraemia on captopril Yes Yes Yes Yes Yes Yes Previous uraemia on captopril No Not proven Prior diuretic, diarrhoea Yes Not proven Congestive heart failure Yes Yes Yes Yes therapy. A number of other patients admitted with baseline values outside the normal range showed decreases in urinary protein excretion while on therapy. Enalapril vs captopril The relative incidence of adverse effects in captopril-treated patients and in enalapriltreated patients is presented in Table 7. The current captopril package insert shows the incidence of rash, taste disturbance, neutropenia and proteinuria which are distinctly higher than those recorded for enalapril. The captopril findings were drawn from the overall worldwide investigational experience, and included the results from early clinical trials when larger doses were used than is currently advocated. Additionally, patients with abnormal renal disease and/or collagen diseases were included, and these bad-risk patients had a higher incidence of side-effects. More recently, the percent of patients discontinued during captopril therapy for adverse effects has been reported and shown for patients with normal renal function and those with impaired renal function (Groel et al., 1983). Unlike earlier reports, these data were collected from patients who have been receiving lower doses of captopril. Data on the incidence of adverse effects not requiring discontinuation are not available. Data reported for enalapril show both the incidence of adverse reactions and the percent of patients discontinued. The most striking comparison is that of patients discontinuing for rash or for taste disturbance. The incidence was lower to nonexistent in the enalapril studies even when compared with low dose captopril in patients with normal renal function. While the incidence of neutropenia or agranulocytosis on captopril varies depending on renal function and underlying disease and has overall a low incidence in good risk patients, no case of significant neutropenia has been encountered with enalapril to date regardless of risk status or dosage level. A variable incidence of proteinuria has been reported on captopril which is higher in the presence of impaired renal function. The relationship to captopril therapy in some of these cases may be debatable, but in any event, no consistent pattern of proteinuria has been documented for enalapril. The definition of proteinuria used in the studies with captopril is quite demanding (Frohlich et al., 1984); not a single case of patients with hypertension treated with enalpril met such criteria. Compassionate use experience Since 1981, compassionate use protocols have been available for those patients who were either resistant to other therapy or who had responded well to captopril but had significant adverse effects requiring discontinuation of therapy. Of 59 patients on whom data are currently available, 34 had been admitted for prior skin rashes from captopril. In only two patients was there a recurrence on enalapril, and in both cases the rash was mild. In the other cases, patients had been maintained on enalapril, some for longer than 12 months, without recurrence. Biollaz et al. (1982) have recently reported three cases of rash and one of rash and fever due to captopril who have responded well and without recurrence on enalapril. Another hypertensive patient with a previous methimazole rash developed a similar eruption on low dose captopril which disappeared without loss of blood pressure control when enalapril was substituted for captopril (Ferguson et al., 1982). Five patients were admitted with significant proteinuria when on captopril; there was one recurrence on enalapril. Overall in these compassionate use protocols, the results with enalapril have confirmed the data from controlled trials and indicate that enalapril is well-tolerated in most patients who
5 Table 7 Tolerance and safety of enalapril Relative incidence of adverse effects in captopril-treated patients and in enalapril-treated patients 253S Enalapril Captopril Occurrence Discontinued Occurrence Discontinued Merck's NDA Labelling current Labelfing* current literaturet literature* Normal Impaired renal renal function function (discontinued) Dose Dose Low-high Low-high Skin rash % % Taste disturbance % % Neutropenia < 300/mm % 0.05% 7.2%f Proteinuria % % *Results not available. tdiscontinued cases, overall incidence not reported, range shown because adverse experience varies with dose level. twith collagen disease Definition of proteinuria as in Frohlich et al. (1984). have experienced adverse effects while on treatment with captopril. We speculate that this is due to the absence of a sulphydryl group in the chemical structure of enalapril. References Biollaz, J., Brunner, H. R., Gavras, I., Waeber, B. & Gavras, H. (1982). Antihypertensive therapy with MK-421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockage. J. cardiovasc. Pharmac., 4, Cressman, M. D., Vidt, D. G. & Acker, C. (1982). Renal glycosuria and azotemia after enalapril maleate (MK-421). Lancet, ii, 440. Ferguson, R. K., Vlasses, P. H., Swanson, B. N., Mojaverian, P., Hichens, M., Irvin, J. D. & Huber, P. B. (1982). Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin. Pharmac. Ther., 32, Frohlich, E. D., Cooper, R. A. & Lewis, E. J. (1984). Review of the overall experience of captopril in hypertension. Arch. Intern. Med., 144,
congestive heart failure
Br. J. clin. Pharmac. (1987), 23, 43-41 The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure K. DICKSTEIN, A. E. TILL, T. AARSLAND, K. TJELTA, A. M. ABRAHAMSEN, K. KRISTIANSON,
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.219 Comparative Study of Adverse Effect of
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationC o n v e r s i b e n a z e p r. l i s i n o p r
C o n v e r s i b e n a z e p r t o l i s i n o p r Ace-inhibitor conversions. Common Medication Conversions (Equivalents) Ace Inhibitors : Drug Comparisons - Home Page. Hydrochlorothiazide; lisinopril
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationStudy of the Side effects profile of different antihypertensive drugs among the Hypertensive patient
Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient Shrestha RK 1, Khan GM 1, Thapa P 1, Koju R 2 1 Department of Pharmacy, Kathmandu University 2 Department
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationConverting iv vasotec to po vasotec
Converting iv vasotec to po vasotec The Borg System is 100 % Retrievable Converting iv vasotec to po vasotec Conversion from IV to oral dosage form. If not concurrently receiving diuretics, initiate enalapril
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationMy cat has kidney problems and food hypersensitivity what do I do now?
TROVET Renal (Venison), complete, easily digestible, hypoallergenic dietary food for adult cats with an impaired kidney function My cat has kidney problems and food hypersensitivity what do I do now? reliable
More informationFortekor 5 mg. Tablets for Dogs and Cats
Date: 9 April 2003 Page: 1 of 7 Carton, main panel PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Info pest Verified Fortekor 5 mg Tablets for Dogs and Cats Active Constituent:
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com
More informationPRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE
Original Article PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE Annamalai Maduram 1, Harikrishna 2 INTRODUCTION High blood pressure, termed "hypertension,"
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluclon 250 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of flucloxacillin as flucloxacillin sodium.
More informationLotrel (amlodipine besylate and benazepril hydrochloride) Combination Capsules
T2004-83 Lotrel (amlodipine besylate and benazepril hydrochloride) Combination Capsules 2.5 mg/10 mg 5 mg/10 mg 5 mg/20 mg 10 mg/20 mg Rx only Prescribing Information USE IN PREGNANCY When used in pregnancy
More informationENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis
GDR11136 ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis February 2012 Summary The challenge data presented in this technical bulletin was completed
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg tablets for dogs Cardalis 5 mg/40 mg tablets for dogs Cardalis 10 mg/80 mg tablets for dogs
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationFrequently asked questions
Frequently asked questions At what stage of heart failure should Cardalis be used? Cardalis should be given as part of your standard heart failure therapy as soon as clinical signs (such as exercise intolerance,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amodip 1.25 mg chewable tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Active substance:
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 January 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 January 2008 ZANIDIP 10mg, film-coated tablets B/28 (CIP: 347 638.7) B/30 (CIP: 372 259.6) B/90 (CIP: 372 260.4)
More informationPublic Assessment Report Scientific discussion. Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC
Public Assessment Report Scientific discussion Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC This module reflects the scientific discussion for the approval
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More information1.1. ACE-inhibitors and flushing
1.1. ACE-inhibitors and Introduction Angiotensin-converting enzyme (ACE) inhibitors are widely used for the treatment of and heart failure. The following ACE-inhibitors are registered in the Netherlands:
More informationDr. Omar S. Tabbouche, M.Sc, D.Sc, Pharm.D Head of Pharmacy Department New Mazloum Hospital Tripoli, Lebanon
Efficacy & Safety of Ketoprofen 25mg vs. Paracetamol 1g intravenous preparations in the management of fever in adults: A pilot, double-blind, parallel-group, randomized controlled trial Dr. Omar S. Tabbouche,
More informationAPPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.
APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationFile S1: Questionnaire for self-medication with antibiotics
File S1: Questionnaire for self-medication with antibiotics Part A: Self-medication behaviors 1 2 3 4 5 6 7 8 Have you ever taken antibiotics? If NO, please go to Part B Question 1 Have you ever treated
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More informationKeywords: Benazepril - Congestive heart failure - Dogs
Long-term tolerability of benazepril in dogs with congestive heart failure Jean-Louis Pouchelon 1 ; Jonathan King; Laure Martignoni; Valérie Chetboul; Béatrice Lugardon; Jean-François Rousselot; Jean-Philippe
More informationOverview. Clinical signs. Will you treat? Owner willing to treat? Surgical vs. Medical. Medical options
Part II (cushing s disease is hard to diagnose) Cushing s Disease Is Easy To Treat Why test? When to test? How to test? Will you treat? How to treat? Overview Thomas Schermerhorn, VMD, DACVIM(SAIM) Kansas
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationHeartworm Disease in Dogs
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Heartworm Disease in Dogs Basics OVERVIEW Disease caused by infestation with heartworms
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationSubmission for Reclassification
Submission for Reclassification Fucithalmic (Fusidic Acid 1% Eye Drops) From Prescription Medicine to Restricted Medicine (Pharmacist Only Medicine) CSL Biotherapies (NZ) Limited 666 Great South Road Penrose
More informationAMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL. Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB]
AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB] ESH/ESC HT MANAGEMENT GUIDELINE 2013 DIAGNOSIS TARGET BP TARGET BP CONTROL
More informationTHE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..
THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy
More informationAmoxicillin dose for gum infection
Amoxicillin dose for gum infection Learn about Prilosec (Omeprazole) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. 30-9-1990 Amoxicillin
More informationPRODUCT MONOGRAPH BENAZEPRIL. Benazepril Hydrochloride. Tablets 5 mg, 10 mg and 20 mg. Angiotensin Converting Enzyme Inhibitor
PRODUCT MONOGRAPH Pr BENAZEPRIL Benazepril Hydrochloride Tablets 5 mg, 10 mg and 20 mg Angiotensin Converting Enzyme Inhibitor AA PHARMA INC. DATE OF REVISION: 1165 Creditstone Road, Unit #1 Vaughan, Ontario
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure flavoured 10 mg Tablets For dogs (Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,,
More informationEnalapril maleate /Hydrochlorothiazide (20 mg/ 12.5 mg tablets) NL/H/0377/001/R/ proposed track version package leaflet Page 1 of 9
proposed track version package leaflet Page 1 of 9 Package leaflet: Information for the user Enalapril maleate/hydrochlorothiazide 20 mg/12.5 mg tablets Enalapril maleate / Hydrochlorothiazide (HCT) Read
More informationZENTEL (Albendazole) PRODUCT INFORMATION
ZENTEL (Albendazole) PRODUCT INFORMATION DESCRIPTION ZENTEL contains albendazole, which is methyl [5-(propylthio)-1H-benzimidazol-2-yl] carbamate. It is a member of the benzimidazole group of anthelmintic
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationDouble-Blind, Placebo-Controlled, Randomized Study of Dipyrone as a Treatment for Pyrexia in Horses
Double-Blind, Placebo-Controlled, Randomized Study of Dipyrone as a Treatment for Pyrexia in Horses Emily Sundman, DVM Ming Yin, PhD Tianhua Hu, PhD Melinda Poole, DVM Disclosures Sundman, Yin, Hu, and
More informationAssessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT,
Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT, Sylva LU SCHWAGER, Edward D STURROCK, Lubbe WIESNER, Brian
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationResponsible use of antimicrobials in veterinary practice
Responsible use of antimicrobials in veterinary practice Correct antimicrobial: as little as possible, as much as necessary This document provides more information to accompany our responsible use of antimicrobials
More informationIJBCP International Journal of Basic & Clinical Pharmacology. Adverse drug effects monitoring of amlodipine in a tertiary care hospital
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20182069 Original Research Article Adverse drug
More informationTreatment of septic peritonitis
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Treatment of septic peritonitis Author : Andrew Linklater Categories : Companion animal, Vets Date : November 2, 2016 Septic
More informationAlprim Trimethoprim PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Active ingredient: Trimethoprim
Alprim Trimethoprim PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Trimethoprim Chemical name: 5-(3,4,5-trimethoxybenzyl)-pyrimidine-2, 4-diamine Structural formula: Molecular formula: C 14
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval
More informationThe 4 th Generation calcium channel blocker C I L N I D I P I N E
T The 4 th Generation calcium channel blocker C I L N I D I P I N E = TOp DUal Action New Ca 2+ Channel Blocker Cilnidipine (IHS) - C 27 H 28 N 2 O 7 INDICATION Essential Hypertension DOSAGE & PACKAGE
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationNew Zealand Data Sheet. Apo-Amlodipine
New Zealand Data Sheet Apo-Amlodipine Presentation APO-AMLODIPINE 2.5mg are white to off-white, round unscored tablets, engraved APO on one side and AML over 2.5 on the other side. Each tablet typically
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationAnaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci
CLINDACIN Composition Each capsule contains Clindamycin (as hydrochloride) 150 mg Capsule Action Clindamycin bind exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis. Clindamycin
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationUnasyn alternative if penicillin allergic
Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.
More informationJob Title Name Signature Date
Supply of Trimethoprim 200mg tablets By Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients Protocol number 473 Version 1 Date protocol prepared: November
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationRestore life and vitality in your dog. Feel the same results as an owner.
Restore life and vitality in your dog. Feel the same results as an owner. Your dog, Cushing s syndrome and you This booklet has been designed to help answer questions that you may have about Cushing s
More informationCOLLEGE OF VETERINARY MEDICINE
Title: A randomized, masked, placebo controlled field study to determine efficacy and safety of Paccal Vet in dogs with non resectable (or unresected) mammary carcinoma of stage III-V 1. Why is the study
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationMaximum antihypertensive effects are attained within 2 weeks after a change in dose. AZOR may be administered with other antihypertensive agents.
Page 4 FULL PRESCRIBING INFORMATION AZOR (amlodipine and olmesartan medoxomil) tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationCODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP Adopted 2005
CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP 61-2005 Adopted 2005 CAC/RCP 61-2005 2 1. INTRODUCTION 2. AIMS AND OBJECTIVES 3. RESPONSIBILITIES OF THE REGULATORY AUTHORITIES
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE
More informationAPO-FLUCLOXACILLIN CAPSULES. sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate.
APO-FLUCLOXACILLIN CAPSULES NAME OF THE MEDICINE Flucloxacillin sodium monohydrate. Chemical Name: sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural Formula:
More informationNovember 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas
Supply of Trimethoprim 200mg tablets by Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients from 16 and 65 years of age. November 2017 Review Nov 2019
More informationLABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More information